MedTrace Logo

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

NCT03135184 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-05-23

No results posted yet for this study

Summary

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Conditions

  • Homozygous Familial Hypercholesterolemia
  • HoFH

Interventions

DEVICE

HDL Therapeutics PDS-2 System

Delipidation of plasma HDL to reduce coronary atheroma

Sponsors & Collaborators

  • MedStar Heart and Vascular Institute

    collaborator UNKNOWN

  • HDL Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-26
Primary Completion
2019-01-07
Completion
2019-08-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03135184 on ClinicalTrials.gov